This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Bursztyn, M. Articles by Rosenthal, T. Search for Related Content PubMed PubMed Citation Articles by Bursztyn, M. Articles by Rosenthal, T. Social Bookmarking                         What's this?

Nifedipine in the Treatment of Hypertension in Systemic Lupus Erythematosus

Department of Medicine D, Hypertension Unit, The Chaim Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Amira Many

Institutes of Hematology, The Chaim Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Talma Rosenthal

Department of Medicine D, Hypertension Unit, The Chaim Sheba Medical Center, Tel-Hashomer, Israel, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel

Treatment of hypertension in systemic lupus erythematosus (SLE) may be complicated by unwanted immunologic vascular and renal side effects of drugs. The safety of long-acting nifedipine tablets was studied in 8 SLE hypertensive subjects for six months. Nifedipine reduced blood pressure from a mean 151.9 ± 10/103.7 ± 8.6 mmHg to a mean of 130 ± 14.1/87.5 ± 5 mmHg. There was no deterioration of renal function or of hematologic or immunologic indices during that period. We believe nifedipine is a safe and effective hypotensive drug in SLE, either alone or combined with beta blockers and diuretics.

Angiology, Vol. 38, No. 5, 359-362 (1987)
DOI: 10.1177/000331978703800502


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?